Monday, 6th December 2021
<To guardian.ng
Search
Breaking News:

NHIS, Roche sign MoU on cancer care reimbursement initiative

By Nkechi Onyedika-Ugoeze, Abuja
23 November 2021   |   3:19 am
National Health Insurance Scheme (NHIS) and Roche Products Nigeria Limited have concluded plans to partner on a cancer care reimbursement initiative.

National Health Insurance Scheme (NHIS) and Roche Products Nigeria Limited have concluded plans to partner on a cancer care reimbursement initiative.

Consequently, the parties signed a Memorandum of Understanding aimed at improving patients’ access to innovative cancer medicines.

The arrangement allows both to partner on an innovative cost-sharing mechanism to ensure the affordability of drugs for patients at treatment centres.

Speaking at the event, General Manager, Roche Products Ltd., Nigeria, Dr. Ladi Hammeed, described the partnership as a significant and commendable milestone for cancer care in Nigeria, expressing optimism that patients will no longer have to deal with the consequences of diagnosis.

He noted that funding for early treatment, comprehensive care – inclusive of surgery, radiotherapy, chemotherapy and targeted therapy – improve treatment outcomes and, ultimately, survival of patients.

He said the partnership enables both healthcare institutions to engage in capability building initiatives that are designed to support the health insurance ecosystem.

In his remarks, Executive Secretary and Chief Executive Officer of NHIS, Prof. Mohammed Sambo, said the Scheme will bring affordable and quality healthcare to all Nigerians, even as he stressed that the implementation of its ten-year strategic plan was on course.

Sambo, who was represented by General Manager, Legal Services, Blessing Nienge, explained that the health insurance regulator and Swiss drug giant will work assiduously to attain Universal Health Coverage (UHC) in Nigeria.

NHIS is Nigeria’s foremost health insurance implementing agency, while Roche is a leading biotech company, with differentiated and innovative medicines in various disease areas, including oncology, immunology, infectious diseases, ophthalmology and the central nervous system.

The partnership will be piloted in designated centres across the six geopolitical zones of the country.